Hans C. Fluehler
Former positions of Hans C. Fluehler
| Companies | Position | End |
|---|---|---|
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Director/Board Member | 2006-03-21 |
Procyon Biopharma, Inc.
 Procyon Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Procyon Biopharma, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative cancer therapeutic, screening, and diagnostic products and technologies. Procyon has acquired four technologies of which two are broad platform technologies. These two are Prostate Secretory Protein (PSP94), for the prostate cancer market, and the ANA technology platform, that has been developed to improve the immune system and resistibility of cancer. The company is headquartered in Dorval in Québec, Canada | Director/Board Member | 2006-03-02 |
Experiences
Positions held
Linked companies
| Private companies | 2 |
|---|---|
Procyon Biopharma, Inc.
Procyon Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Procyon Biopharma, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative cancer therapeutic, screening, and diagnostic products and technologies. Procyon has acquired four technologies of which two are broad platform technologies. These two are Prostate Secretory Protein (PSP94), for the prostate cancer market, and the ANA technology platform, that has been developed to improve the immune system and resistibility of cancer. The company is headquartered in Dorval in Québec, Canada | Commercial Services |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
- Stock Market
- Insiders
- Hans C. Fluehler
